ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities.

March 22, 2002

In Brief: Jordan To Join MD Anderson Cancer Center

July 25, 2014

In Brief: NCI To Supply Maytansine For Several Phase I Studies; Holleb Urges Referrals To “Experts”

March 26, 1976

Administration’s FY 1981 Budget Would Leave Gaps, Curtail Many Program, Without New Cuts

March 28, 1980

R.S.K. Young Quits As FDA Oncology Group Leader

July 11, 1980

Breast Cancer Survivors Report More Severe Fatigue Than Healthy Women

September 28, 2007